Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 8/20 | 0.36 |
| ▸ | CDK9 | P50750 | 8/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.36 |
| ▸ | CDK2 | P24941 | 7/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.35 |
| ▸ | CDC42BPB | Q9Y5S2 | 9/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.31 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1802877 | 0.87 | ROCK1 (0.46) | CCNT1CDK9CDK5CDK5R1CCNA2 | |
| SCHEMBL1802365 | 0.75 | BRD4 (0.35) | — | |
| SCHEMBL1799953 | 0.74 | ROCK1 (0.43) | CCNT1CDK9CDK5CDK5R1CCNA2 | |
| SCHEMBL2753851 | 0.70 | ROCK2 (0.55) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL1799236 | 0.67 | CDK1 (0.36) | — | |
| SCHEMBL1802369 | 0.64 | PTGDR2 (0.38) | CDK2 | |
| SCHEMBL15500785 | 0.63 | MEN1 (0.39) | ROCK1 | |
| SCHEMBL2237463 | 0.62 | CDK5 (0.65) | CCNT1CDK9CDK5CDK5R1CCNA2 | |
| SCHEMBL1800868 | 0.62 | PDPK1 (0.53) | CCNT1CDK9CDK5CCNA2CDK2 | |
| SCHEMBL12338414 | 0.62 | PDPK1 (0.40) | CCNT1CDK9CDK5CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2125801-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | CCNT1 1826/4885CDK9 381/4885CDK5 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.